Navamedic extends distribution of Imdur to four new European markets
Oslo, 1 March 2017 – Navamedic ASA (OSE: NAVA),
the Norwegian medtech and pharmaceutical products company, today announced it is expanding distribution of the angina prevention medicine, Imdur®, to the United Kingdom, Ireland, Malta and Cyprus during the month of March, bringing the distribution to a total of thirteen markets across Europe.
Imdur® is part of a strategic partnership with TopRidge
Pharma Limited (TopRidge Pharma), under which the product has
become Navamedic’s largest single brand.
Navamedic